Glucagon-like peptide-1 receptor agonists, which include Ozempic and Mounjaro, cost between five to 10 times more in the U.S. than other wealthy nations, according to research KFF published Aug. 17.
In the U.S., Type 2 diabetes drugs Ozempic, Rybelsus and Mounjaro, and the weight loss medication Wegovy, cost between $936 and $1,349 for a month's supply.
Japan, the country with the second-highest average cost for this popular class of medications, is five times less. There, Ozempic costs about $170, Rybelsus is $69 and Mounjaro is about $320.
List prices in other nations are significantly 10 times less: In France, Australia, the U.K., Sweden the Netherlands and Germany, Ozempic is between $80 and $100, according to the analysis.